{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:33:42Z","timestamp":1791941622067,"version":"4.3.4"},"reference-count":15,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diagnosing primary central nervous system lymphoma (PCNSL) frequently requires neurosurgical biopsy due to nonspecific radiologic features and the low yield of cerebrospinal fluid (CSF) studies. We characterized the clinical evaluation of suspected PCNSL (N = 1007 patients) and designed a rapid multiplexed genotyping assay for MYD88, TERT promoter, IDH1\/2, H3F3A, and BRAF mutations to facilitate the diagnosis of PCNSL from CSF and detect other neoplasms in the differential diagnosis. Among 159 patients with confirmed PCNSL, the median time to secure a diagnosis of PCNSL was 10 days, with a range of 0 to 617 days. Permanent histopathology confirmed PCNSL in 142 of 152 biopsies (93.4%), whereas CSF analyses were diagnostic in only 15\/113 samplings (13.3%). Among 86 archived clinical specimens, our targeted genotyping assay accurately detected hematologic malignancies with 57.6% sensitivity and 100% specificity (95% confidence interval [CI]: 44.1% to 70.4% and 87.2% to 100%, respectively). MYD88 and TERT promoter mutations were prospectively identified in DNA extracts of CSF obtained from patients with PCNSL and glioblastoma, respectively, within 80 minutes. Across 132 specimens, hallmark mutations indicating the presence of malignancy were detected with 65.8% sensitivity and 100% specificity (95% CI: 56.2%-74.5% and 83.9%-100%, respectively). This targeted genotyping approach offers a rapid, scalable adjunct to reduce diagnostic and treatment delays in PCNSL.<\/jats:p>","DOI":"10.1182\/blood.2020010137","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T22:16:55Z","timestamp":1616105815000},"page":"382-386","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["A rapid genotyping panel for detection of primary central nervous system lymphoma"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1329-2906","authenticated-orcid":false,"given":"Mihir","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"},{"name":"Department of Neurosurgery, University of California San Diego, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Z.","family":"Georgantas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Thierauf","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Experimental Head and Neck Oncology, Heidelberg University Hospital, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-8404","authenticated-orcid":false,"given":"Naema","family":"Nayyar","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SooAe S.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pisapia","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Velarde","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-106X","authenticated-orcid":false,"given":"Brian V.","family":"Nahed","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4573-3641","authenticated-orcid":false,"given":"Pamela S.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8036-1847","authenticated-orcid":false,"given":"William T.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-960X","authenticated-orcid":false,"given":"Rajiv","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Neurology, Brigham and Women's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier M.","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"},{"name":"Department of Neurology,"},{"name":"Division of Hematology\/Oncology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetal D.","family":"Marble","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"},{"name":"Center for Integrated Diagnostics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-7562","authenticated-orcid":false,"given":"Maria","family":"Martinez-Lage","sequence":"additional","affiliation":[{"name":"C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-9013","authenticated-orcid":false,"given":"Kensuke","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yokohama City University, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-4978","authenticated-orcid":false,"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob S.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh M.","family":"Shankar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"1","key":"2021080515250408800_B1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10072-015-2353-4","article-title":"Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme","volume":"37","author":"Cerqua","year":"2016","journal-title":"Neurol Sci"},{"issue":"22","key":"2021080515250408800_B2","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and management of primary central nervous system lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2021080515250408800_B3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/dc.23539","article-title":"Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: A systematic review","volume":"44","author":"Canovi","year":"2016","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"2021080515250408800_B4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"2021080515250408800_B5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"2021080515250408800_B6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","article-title":"MYD88 L265P mutation in lymphoid malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"2021080515250408800_B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"26","key":"2021080515250408800_B8","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"issue":"7741","key":"2021080515250408800_B9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"issue":"7384","key":"2021080515250408800_B10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma [published correction appears in Nature. 2012;484(7392):130]","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"36","key":"2021080515250408800_B11","doi-asserted-by":"crossref","first-page":"E8388","DOI":"10.1073\/pnas.1805751115","article-title":"Genotype-targeted local therapy of glioma","volume":"115","author":"Shankar","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2021080515250408800_B12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"2021080515250408800_B13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-015-1461-9","article-title":"TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium","volume":"130","author":"Bruno","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2021080515250408800_B14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/noy201","article-title":"Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma","volume":"21","author":"Bale","year":"2019","journal-title":"Neuro-oncol"},{"issue":"5","key":"2021080515250408800_B15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/5\/382\/1816198\/bloodbld2020010137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/5\/382\/1816198\/bloodbld2020010137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T16:52:02Z","timestamp":1628182322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/5\/382\/475579\/A-rapid-genotyping-panel-for-detection-of-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3,18]]},"published-print":{"date-parts":[[2021,8,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020010137","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}